GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated February 13, 2025, serves as a transaction notification for the month of February 2025. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 31 1/4 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: £14.5567 per share.
- Transaction Volume: Ranged from 16 to 18 shares per executive.
- Transaction Date: February 11, 2025.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It strictly reports routine equity compensation acquisitions by senior management.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16.
Investor Verification Points
- Verify the total number of shares acquired by each PDMR listed (Emma Walmsley, Julie Brown, James Ford, Sally Jackson, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, Victoria Whyte).
- Confirm the transaction price of £14.5567 aligns with the market price on February 11, 2025.
- Note that these acquisitions were made under the Company's Share Reward Plan, consisting of partnership and matching shares.